Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Asuransi Kesehatan merupakan jawaban dari sifat yang tidak pasti dari kejadian sakit dan kebutuhan akan pelayanan kesehatan, dimana sakit yang merupakan suatu resiko yang ditransfer pada pihak lain yaitu asuransi. Undang-undang SJSN No 40 tahun 2004 dan UU No 24 tahun 2011 tentang BPJS mengamanatkan semua komunitas kesehatan untuk dapat menyediakan pelayanan kesehatan yang bermutu, merata dan terjangkau bagi seluruh masyarakat. Selain itu, pemerintah juga harus dapat menjamin tersedianya pelayanan kesehatan sampai ke daerah terpencil dan penduduk miskin.1 Januari 2014 Jaminan Sosial Kesehatan mulai dilaksanakan di Indonesia dan menggunakan model tarif INA CBGs untuk pembayaran klaim nya. Penelitian ini dilakukan untuk Gambaran Manajemen Klaim Rawat Inap Badan Penyelenggara Jaminan Sosial Kesehatan di Rumah Sakit Umum Daerah Pasar Rebo 2014. Penelitian ini menggunakan metode kualitatif dengan cara wawancara mendalam, observasi dan telaah dokumen. Klaim dilakukan agar pihak ketiga dapat membayarkan seluruh pelayanan kesehatan yang telah diberikan rumah sakit kepada peserta BPJS. Hasil penelitian ini menunjukkan pengelolaan klaim yang cukup baik. Perlu dilakukan evaluasi terhadap penulisan rekam medik agar mengurangi selisih klaim agar dapat meminimalisir resiko tersebut. ...... Health insurance is the answer to the uncertainty of illness occurrence and the need for health care, where pain is a risk that is transferred to the third party, which is the insurance. The Laws of SJSN No. 40 of 2004 and The Laws No. 24 of 2011 about BPJS mandatethat all health communities should be able to provide the good quality health care, equitable and affordable to all societies. In addition, the government also must be able to ensure the availability of health services to remote areas and the poor. January 1st, 2014,Health Social Insurance began to be implemented in Indonesia and used models INA CBGs for the payment of the claim. This study was conducted to determine the overview of hospitalization claim management of The Healthcare and Social Security Agency (BPJS Kesehatan) at Pasar Rebo Hospital in 2014. This study used a qualitative method bymeans of in-depth interviews, observations and documents? analysis. The claim is done so that the third parties may pay the entire hospital's health cares that have been given to the participants of BPJS. These results indicate a fairly good claim management. It is Necessary to evaluate the writing of medical records in order to reduce the difference in the claims to minimize the risk.

Abstrak :
Penelitian ini dilakukan untuk mengetahui gambaran tentang pengelolaan klaim rawat inap jaminan KJS di RSUD Pasar Rebo tahun 2013. Program KJS sendiri sudah berjalan sekitar bulan November 2012 dan baru menggunakan model tarif INA CBGs pada bulan April 2013. Penelitian ini menggunakan metode kualitatif dengan cara wawancara mendalam, observasi dan telaah dokumen. Klaim dilakukan agar pihak ketiga dapat membayarkan seluruh pelayanan kesehatan yang telah diberikan rumah sakit kepada peserta KJS. Hasil penelitian ini menunjukkan pengelolaan klaim yang cukup baik. Perlu dilakukan evaluasi terhadap penulisan rekam medik agar mengurangi selisih klaim dan pihak manajemen perlu menerapkan clinical pathway agar dapat meminimalisir resiko tersebut. ...... This study was conducted to describe about the claim management of inpatient for KJS insurance at General Hospital Pasar Rebo in year 2013. The KJS program itself has been implemented since November 2012 and has just been using the Tariff Model of INA CBGs in April 2013. This study uses qualitative research with in-depth interviews, observation and document review. The General Hospital managed the in-patient claim to the third parties so they can reimburse back for any hospital services they did for the KJS insurance participants. The result of this study shows the well-managed claim management. But it is still necessary to evaluate the medical records data entries to eliminate claim difference and the hospital management needs to apply some clinical pathways for the same purpose.

Abstrak :
[ABSTRAK
Latar belakang:Hipertensimerupakan salah satu faktor risiko gagal jantung kongestif. Di rawat inap RSUD Pasar Rebo pada tahun 2014, gagal jantung kongestif masuk dalam 10 penyakit terbanyak, dengan biaya total yang cukup besar dan terdapat selisih tarif antara tarif RS dengan tarif JKN, sehingga perlu dilakukan analisis minimalisasi biaya salah satunya pada obat antihipertensi. Tujuan: Penelitian ini bertujuan untuk memilih alternatif yang lebih cost- minimize antara ramipril-spironolakton dengan valsartan pada pengobatan gagal jantung kongestif di RSUD Pasar Rebo tahun 2014. Metode Penelitian: Penelitian ini merupakan penelitian kuantitatifberupa analisis cross-sectional retrospektif. Penelitian dilakukan dengan membandingkan nilai rata-rata biaya total dua alternatif pengobatan gagal jantung kongestif, yaitu ramipril-spironolakton dengan valsartan dengan menggunakan perspektif Rumah Sakit. Komponen biaya langsung medis yang dihitung adalah biaya obat, biaya jasa dokter dan biaya rawat inap. Sedangkan efektivitas dipastikan memiliki efek yang setara. Hasil: Berdasarkan hasil penelitian yang telah dilakukan pada pasien gagal jantung kongestif di RSUD Pasar Rebo tahun 2014 didapatkan bahwa: (1) Nilairata-rata biaya total penggunaan kombinasi obat ramipril-spironolakton sebesar Rp.2.527.743; (2) Rata-rata biaya total penggunaan obat valsartan sebesar Rp.2.430.923; (3) Obat ramipril-spironolakton efektivitasnya tidak berbeda signifikan atau setara dengan obat valsartan; (4) Adanya penghematan pada rata- rata biaya total obat valsartan sebesar Rp.96.820 per pasien; (5) Adanya penghematan pada biaya rawat inap obat valsartan sebesar Rp.299.031 per pasien. Kesimpulan: Obat valsartan memberikan nilai rupiah yang terendah dan menjadi pilihan yang lebih cost-minimize dibandingkan obat ramipril-spironolakton pada pasien gagal jantung kongestif di RSUD Pasar Rebo Tahun 2014.

---

ABSTRACT
Background: Hypertension once of risk factor for congestive heart failure. The Pasar Rebo Hospital inpatient care in 2014, congestive heart failure is the top 10 most prevalent diseases, with a large of number total cost and there is a difference between tariff rates RS and JKN rate, so we need a cost-effectiveness analysis one with antihypertensive drug. Objective: This study aimed to choose an alternative that is more cost-minimize between the ramipril-spironolactone with valsartan in the treatment of congestive heart failure at Pasar Rebo Hospital in 2014. Methods: This is a quantitative research in the form of a retrospective cross- sectional analysis. The study was conducted by comparing the average value of total cost of two alternative treatment of congestive heart failure, ramipril- spironolactone with valsartan by using Hospital’s perspective. The direct medical cost component are cost of drugs, cost of physician services and cost of hospitalizations. Whereas effectiveness measuredand firmly to be equivalent. Results: Based on the research that has been conducted in patients with congestive heart failure at Pasar Rebo Hospital in 2014 found that: (1) The average total cost of ramipril-spironolactone’s drugare Rp.2.527.743; (2) The average total cost of valsartan’s drug are Rp.2.430.923; (3) Ramipril- spironolactone’s drug effectiveness does not significantly difference to valsartan’s drug; (4) There is cost saving on the average of total cost using valsartan’s drug Rp.96.820 per patient; (5) There is cost saving on hospitalization cost using valsartan’s drug Rp.299.031 per patient. Conclusions:V alsartan’ s drug give lowest rupiah value and be more cost minimizes option than ramipril-spironolactone’s drug for patient with congestive heart failure at Pasar Rebo Hospital in 2014., Background: Hypertension once of risk factor for congestive heart failure. The Pasar Rebo Hospital inpatient care in 2014, congestive heart failure is the top 10 most prevalent diseases, with a large of number total cost and there is a difference between tariff rates RS and JKN rate, so we need a cost-effectiveness analysis one with antihypertensive drug. Objective: This study aimed to choose an alternative that is more cost-minimize between the ramipril-spironolactone with valsartan in the treatment of congestive heart failure at Pasar Rebo Hospital in 2014. Methods: This is a quantitative research in the form of a retrospective cross- sectional analysis. The study was conducted by comparing the average value of total cost of two alternative treatment of congestive heart failure, ramipril- spironolactone with valsartan by using Hospital’s perspective. The direct medical cost component are cost of drugs, cost of physician services and cost of hospitalizations. Whereas effectiveness measuredand firmly to be equivalent. Results: Based on the research that has been conducted in patients with congestive heart failure at Pasar Rebo Hospital in 2014 found that: (1) The average total cost of ramipril-spironolactone’s drugare Rp.2.527.743; (2) The average total cost of valsartan’s drug are Rp.2.430.923; (3) Ramipril- spironolactone’s drug effectiveness does not significantly difference to valsartan’s drug; (4) There is cost saving on the average of total cost using valsartan’s drug Rp.96.820 per patient; (5) There is cost saving on hospitalization cost using valsartan’s drug Rp.299.031 per patient. Conclusions:V alsartan’ s drug give lowest rupiah value and be more cost minimizes option than ramipril-spironolactone’s drug for patient with congestive heart failure at Pasar Rebo Hospital in 2014.]